Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elixir Pharmaceuticals Inc.

www.elixirpharm.com

Latest From Agfa-Gevaert Group

Imaging Market Could See Brighter Days Ahead

More than two years into a prolonged economic slump that depressed capital equipment sales and weakened stock prices, manufacturers of diagnostic imaging equipment appear to have reason to smile again as hospitals restart the process of acquiring new equipment to replace aging technology.
Medical Device

TomoTherapy: Niche Player or Not?

Radiation oncology is a very attractive market indeed. It's a $3 billion-plus capital equipment market predicted to experience a compound annual growth rate of 10 to 15% in the next several years, with the image-guided segment expected to grow at a 35% rate. Approximately 30% of the market is up for grabs over the next three years, as institutions replace old and obsolete equipment. Can small company TomoTherapy sustain the lead it has gained with a new image-guided system that increases the precision of cancer targeting and spares normal tissues, once entrenched multi-billion dollar radiation oncology companies begin to offer aggressive competition?
Medical Device Strategy

Breast Cancer: Improving the Odds

Breast cancer is the most common type of female cancer and the number two cancer killer in US women. Treatment options continue to expand and researchers are making steady advancements in cancer detection that they hope will one day enable most breast cancer cases to be diagnosed an an early, very curable stage.
Medical Device

PhorMax Corp.

PhorMax Corp. hopes to make filmless medical images affordable and widely accessible with CRView, its low-cost computed radiography system. CRView combines an imaging system and Web-based communications infrastructure to incorporate radiology images with other data in an electronic patient record, and facilitate its distribution within an institution or to interested parties on the outside. CRView will be priced at approximately $50,000, less than half the price of existing systems. And it is compatible with existing X-ray systems, which will allow imaging centers to become filmless without having to replace or reconfigure their existing equipment.
Medical Device Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Elixir Pharmaceuticals Inc.
  • Senior Management
  • Paul M Martha, MD, CEO & CMO
    Peter S DiStefano, PhD, CSO
  • Contact Info
  • Elixir Pharmaceuticals Inc.
    Phone: (617) 995-7000
    12 Emily St.
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register